(IN BRIEF) Sanofi has simplified its contractual arrangements with AstraZeneca and Sobi for the development and commercialization of Beyfortus (nirsevimab)…
(ACTUALITÉ EN BREF) The Co-operative Group Limited a annoncé qu'Adrian Marsh rejoindrait la société en tant qu'administrateur non exécutif indépendant…
(IN BRIEF) The Co-operative Group Limited has announced that Adrian Marsh will join the company as an Independent Non-Executive Director…
(ACTUALITÉ EN BREF) AstraZeneca a lancé le Défi postdoctoral R&D 2023, qui invite les étudiants en dernière année de médecine…
(IN BRIEF) AstraZeneca has launched the 2023 R&D Postdoctoral Challenge, which invites final-year MD and/or PhD students and postdoctoral researchers…
(PRESS RELEASE) CAMBRIDGE, 16-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the…
(COMUNICADO DE PRENSA) CAMBRIDGE, 16-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), una multinacional británica-sueca farmacéutica y de biotecnología, ha anunciado…
(PRESS RELEASE) CAMBRIDGE, 13-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced that…
(COMUNICADO DE PRENSA) CAMBRIDGE, 13-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), una multinacional británica-sueco-farmacéutica y biotecnológica, ha anunciado que su…
(PRESS RELEASE) CAMBRIDGE, 2-Nov-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced fully…
(PRESSEMITTEILUNG) CAMBRIDGE, 2-Nov-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), ein britisch-schwedisches multinationales Unternehmen Pharma- und Biotechnologieunternehmen, hat voll finanzierte Postdoktoranden-Forschungsstellen…
El desafío tiene como objetivo ayudar al descubrimiento de avances transformadores en las áreas de enfermedades centrales de AstraZeneca. Las…
The challenge aims at helping the discovery of transformative breakthroughs across AstraZeneca’s core disease areas Successful proposals will secure fully…
(COMMUNIQUÉ DE PRESSE) CAMBRIDGE, 16-Feb-2022 — /EuropaWire/ — AstraZeneca (LON : AZN), une multinationale pharmaceutique et biotechnologique anglo-suédoise , a annoncé…
(PRESS RELEASE) CAMBRIDGE, 16-Feb-2022 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced an…
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal…
(PRESS RELEASE) CAMBRIDGE, 5-Jan-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the…
Agreement sharpens AstraZeneca’s focus on priority medicines in Respiratory & Immunology portfolio (PRESS RELEASE) CAMBRIDGE, 1-Nov-2021 — /EuropaWire/ — AstraZeneca…
(PRESS RELEASE) CAMBRIDGE, 29-Sep-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced its…
(PRESS RELEASE) CAMBRIDGE, 24-Sep-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical and biopharmaceutical company, has announced positive…
(PRESS RELEASE) CAMBRIDGE, 3-Sep-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical and biopharmaceutical company, has announced an…
(PRESS RELEASE) CAMBRIDGE, 2-Aug-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish science-led biopharmaceutical company, has announced that its Saphnelo…
Increased efficacy with longer inter-dose interval Protection of over 70% starting after a first dose First indication of reduction in…
(PRESS RELEASE) CAMBRIDGE, 14-Aug-2020 — /EuropaWire/ — Global science-led biopharmaceutical company AstraZeneca (LSE/STO/NYSE: AZN) has announced it signed an agreement…
ACE-CL-001 trial showed an overall response rate of 97% with a sustained safety profile for previously untreated patients after more…
(PRESS RELEASE) CAMBRIDGE, 5-Jun-2020 — /EuropaWire/ — British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca announced it will present new data…
(PRESS RELEASE) CAMBRIDGE, 22-May-2020 — /EuropaWire/ — Enhertu, jointly developed by British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca and the…
The trial, called CALAVI, will assess the effect of Calquence on the exaggerated immune response of patients hospitalised with COVID-19…
(PRESS RELEASE) CAMBRIDGE, 26-Mar-2020 — /EuropaWire/ — Science-led biopharmaceutical group AstraZeneca (LSE/STO/NYSE: AZN) has announced that its Lokelma (sodium zirconium…
(PRESS RELEASE) BASEL, 6-Jan-2020 — /EuropaWire/ — ChemChina and Sinochem announce the creation of Syngenta Group. The new holding company…
AstraZeneca / BenevolentAI artificial intelligence collaboration will accelerate drug discovery Potential new drugs discovery in the area of chronic kidney…
27 scientific presentations, including long-term data from Calquence in mantle cell lymphoma and updated early-phase trial results in chronic lymphocytic…
CAMBRIDGE, 07-Nov-2018 — /EuropaWire/ — AstraZeneca has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its…
AstraZeneca’s first Breakthrough Therapy Designation for a respiratory medicine Designation based on Phase IIb PATHWAY data that demonstrated tezepelumab significantly…
Lynparza met primary endpoint of progression-free survival in women with BRCA-mutated advanced ovarian cancer and showed a safety profile consistent…
Trial meets the primary endpoint of durable complete response Majority of patients who had a complete response had no evidence…
Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2…
Lynparza is the first PARP inhibitor approved in Japan Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed…
Imfinzi improves progression-free survival (PFS) by more than 11 months compared to standard of care and is the first medicine…
Phase III FLAURA trial results show Tagrisso reduced the risk of progression or death by more than half, with consistent…